Sulindac inhibits growth of rat colon carcinoma by inducing apoptosis

Eur Surg Res. 2000;32(5):305-9. doi: 10.1159/000008780.


Sulindac possesses an inhibitory effect on colorectal cancer development. Rat colon cancer cells, ACL-15, inoculated subcutaneously in F344 rats were used. Sulindac was administered at 8 mg/kg twice daily for 7 consecutive days. Sulindac group and control group were compared regarding tumor volume and body weight. At sacrifice, the tumors were collected and examined for tumor-infiltrating lymphocytes, apoptotic index, and microvessel density. The tumor volume in the sulindac group was significantly smaller than that in the control group. Body weight, microvessel density, and tumor-infiltrating lymphocyte score were not significantly different between the two groups. The apoptotic index was significantly higher in the sulindac group than in the control group. Sulindac inhibited tumor growth by inducing apoptosis. These findings may be helpful in designing new treatment strategies in colorectal cancer patients.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Apoptosis*
  • Blood Vessels / pathology
  • Carcinoma / blood supply
  • Carcinoma / pathology*
  • Cell Division / drug effects
  • Colonic Neoplasms / blood supply
  • Colonic Neoplasms / pathology*
  • Lymphocytes, Tumor-Infiltrating / pathology
  • Male
  • Neoplasm Transplantation
  • Rats
  • Rats, Inbred F344
  • Sulindac / pharmacology*


  • Anti-Inflammatory Agents, Non-Steroidal
  • Sulindac